Trv Gp Iii is an investment fund managing more than $18.2 billion ran by Kevin Gillis. There are currently 2 companies in Mr. Gillis’s portfolio. The largest investments include Decibel Therapeutics, Inc. and Pliant Therapeutics, together worth $18.2 billion.
As of 3rd August 2023, Trv Gp Iii’s top holding is 3,139,685 shares of Decibel Therapeutics, Inc. currently worth over $12.1 billion and making up 66.3% of the portfolio value.
In addition, the fund holds 339,160 shares of Pliant Therapeutics worth $6.15 billion, whose value fell 42.7% in the past six months.
Currently, Trv Gp Iii's portfolio is worth at least $18.2 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Trv Gp Iii office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Kevin Gillis serves as the Chief Operating Officer at Trv Gp Iii.
There are companies that Trv Gp Iii is getting rid of from its portfolio.
Trv Gp Iii closed its position in Revolution Medicines Inc on 10th August 2023.
It sold the previously owned 3,604,130 shares for $71.1 million.
Kevin Gillis also disclosed a decreased stake in Pliant Therapeutics by 0.9%.
This leaves the value of the investment at $6.15 billion and 339,160 shares.
The two most similar investment funds to Trv Gp Iii are Ayrton Capital and Freemont Capital Pte Ltd. They manage $18.2 billion and $18.2 billion respectively.
Trv Gp Iii’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 33.7% of
the total portfolio value.
The fund focuses on investments in the United States as
50.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $935 million.
These positions were updated on August 10th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Decibel Therapeutics, Inc. |
No change
3,139,685
|
$12,087,787,000 | 66.29% |
| Pliant Therapeutics, Inc. |
91.17%
339,160
|
$6,145,579,000 | 33.71% |
| Revolution Medicines Inc |
Closed
3,604,130
|
$71,073,000 | |
| Voyager Therapeutics Inc |
Closed
5,428,933
|
$32,139,000 | |
| Fulcrum Therapeutics Inc |
Closed
3,962,202
|
$32,054,000 | |
| Jounce Therapeutics Inc |
Closed
1,148,780
|
$2,688,000 | |
| No transactions found | |||
| Showing first 500 out of 6 holdings | |||